Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

avanos medical australia pty ltd - 45405 - orthopaedic x-ray ruler - the epsilon ruler is used a measuring guide on the skin of the patient in the sacroiliac region as a reference to place radiofrequency probes in proper position around the sacroiliac foramen. the device is visible under fluoroscopy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 46395 - corneal bur handpiece, battery-powered - a battery-powered, hand-held slow rotating reusable device designed to perform corneal, and other ophthalmic tissue, abrasion through a bur attached to its distal tip. it is used (with appropriate burs/tips) to clean rust rings from the cornea after the extraction of a ferrous foreign object, to polish corneal scratches and/or the pterygium bed after surgical removal, and/or for abrasion of lid margin lesions.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 12726 - holder, needle - a reusable instrument made of high grade steel or titanium whose blades distal to the pivot point culminate in various shapes to grasp suture needles during surgery

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 35251 - probe, surgical, eye - a reusable slender rodlike instrument made of flexible metal comes in various design and shapes, used during ophthalmic procedure for exploring eye tissue

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 12143 - tray, instrument - a flat shallow vessel, usually with a raised rim, providing a suitable platform for containing many medical, usually surgical instruments and items. it is typically made of stainless steel and designed to fit into other devices, e.g. supply trolleys, storage systems or sterilizers.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 35349 - speculum, eye - a surgical instrument that comprises of two arms joined at a pivot point, and which is available in various sizes, shapes and contours. it has a blunt distal tip and is used for expanding or stretching the tissue around the eye cavity when inserted and opened. it is used for examination or during ophthalmic surgery. it is usually made of stainless steel or titanium with a self-opening or adjustable mechanism. it is reusable instrument.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 46848 - ophthalmic scissors, anterior/posterior segment, reusable - an ophthalmic surgical non sterile instrument made of metal(steel or titanium) used to cut typically a membrane or tissue in anterior or posterior segment during surgery. it is typically: 1) two pivoted blades that may be provided with a finger and thumb ring-handle or spring cross action body which cut with a shearing action (i.e., the blades cut as the sharpened edges pass one another when operated); or 2) an instrument tip, with cutting blades at the distal end, that is locked into a dedicated handle through which the blades are operated. it is available in various sizes and designs. this is a reusable device

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

faro care pty ltd - 16209 - forceps, ophthalmic - a surgical instrument designed with two handles attached to two blades. the handles are permanently joined together, by pressure, during use. ophthalmic forceps are used to grasp, manipulate, compress, pull, or join eye tissue and surrounding tissues.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 12.25 mg (equivalent: lenvatinib, qty 10 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; iron oxide red; calcium carbonate; propylene glycol; hyprolose; mannitol; potassium hydroxide; titanium dioxide; hypromellose; iron oxide black; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 4.9 mg (equivalent: lenvatinib, qty 4 mg) - capsule, hard - excipient ingredients: iron oxide yellow; propylene glycol; potassium hydroxide; mannitol; iron oxide black; titanium dioxide; hypromellose; purified talc; iron oxide red; calcium carbonate; microcrystalline cellulose; hyprolose; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.,differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).